- Home
- SVII vs MIST Comparison
SVII vs MIST Comparison
Compare SVII & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- MIST
- Stock Information
- Founded
- SVII 2021
- MIST 2003
- Country
- SVII United States
- MIST Canada
- Employees
- SVII N/A
- MIST N/A
- Industry
- SVII Blank Checks
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- MIST Health Care
- Exchange
- SVII Nasdaq
- MIST Nasdaq
- Market Cap
- SVII 112.9M
- MIST 98.1M
- IPO Year
- SVII 2022
- MIST N/A
- Fundamental
- Price
- SVII $11.45
- MIST $1.81
- Analyst Decision
- SVII
- MIST Strong Buy
- Analyst Count
- SVII 0
- MIST 2
- Target Price
- SVII N/A
- MIST $17.00
- AVG Volume (30 Days)
- SVII 3.0K
- MIST 1.2M
- Earning Date
- SVII 01-01-0001
- MIST 03-20-2025
- Dividend Yield
- SVII N/A
- MIST N/A
- EPS Growth
- SVII 13.16
- MIST N/A
- EPS
- SVII 0.36
- MIST N/A
- Revenue
- SVII N/A
- MIST N/A
- Revenue This Year
- SVII N/A
- MIST N/A
- Revenue Next Year
- SVII N/A
- MIST N/A
- P/E Ratio
- SVII $31.75
- MIST N/A
- Revenue Growth
- SVII N/A
- MIST N/A
- 52 Week Low
- SVII $10.92
- MIST $1.12
- 52 Week High
- SVII $11.70
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- SVII 89.72
- MIST 43.76
- Support Level
- SVII $11.20
- MIST $1.57
- Resistance Level
- SVII $11.45
- MIST $1.96
- Average True Range (ATR)
- SVII 0.01
- MIST 0.18
- MACD
- SVII 0.01
- MIST -0.00
- Stochastic Oscillator
- SVII 100.00
- MIST 47.69
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).